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Context: Obesity and type 2 diabetes mellitus are associated with
increased levels of IL-6, a marker of inflammation.
Objective: This study addressed the question of whether IL-6 was
released from skeletal muscle after a high-fat meal in men with
impaired glucose tolerance (IGT), a prediabetic state, and whether
IL-6 release could be reduced by weight loss.
Design: Skeletal muscle metabolism was studied in men with IGT
(n 11) and comparedwithmenwith normal glucose tolerance (NGT,
n  9), matched for body mass index and age. IL-6 flux over skeletal
muscle was measured with the forearm model. Eight IGT men were
willing to participate in a 12-wk weight loss program and were tested
again.
Results: IL-6, but not C-reactive protein or TNF- receptor 1 and 2,
was released by skeletal muscle. Muscle IL-6 release was higher in
IGT than in NGT during fasting (IGT 2.26 1.89 vs.NGT 0.87
0.48 fmol100 ml tissue1min1, P  0.04) and after a meal (mean
area under the curve perminute: IGT 3.48 2.63 vs.NGT 1.37
0.75 fmol100 ml tissue1min1; P  0.03). In the IGT men, body
weight loss resulted in a decrease of postprandial IL-6 release from
skeletal muscle (52%; P  0.04), reaching levels of the obese, NGT
controls.
Conclusion:The present data suggest that a high-fatmeal can evoke
IL-6 release from muscle and that the IL-6 release is a consequence
rather than a cause of the obese, insulin-resistant, and/or IGT state.
(J Clin Endocrinol Metab 90: 5819–5824, 2005)
OBESITY AND TYPE 2 diabetes mellitus (DM2) havebeen associated with subclinical inflammation. Mark-
ers of inflammation, like the cytokine IL-6 and the acute-
phase proteinC-reactive protein (CRP), are elevated in obese,
insulin-resistant subjects (1–3). Also TNF- receptors, as
markers for TNF- action (4), and to a lesser extent TNF-
itself, have been found to be elevated in patients with DM2
(3) and, in some studies, also in subjects with impaired glu-
cose tolerance (IGT), a prediabetic state (5). IL-6 is a cytokine
that is produced bymany cell types and is increased in cancer
cachexia (6), after endotoxin stimulation (7) and after vacci-
nation (8). IL-6 is also increased in obesity, insulin resistance,
and DM2, and plasma IL-6 has been shown to be predictive
of the development of DM2 in several prospective studies (9,
10). So, besides its role in inflammation, IL-6 may also affect
insulin sensitivity or glucose metabolism.
It was suggested that IL-6 may cause insulin resistance in
organs like liver and skeletal muscle. In human HepG2 cells
and primary mouse hepatocytes, IL-6 has been shown to
impair insulin signaling by reducing the tyrosine phosphor-
ylation of insulin receptor substrate (IRS)-1 and reducing the
association of the p85 subunit of phosphatidylinositol 3-ki-
nase with IRS-1 (11). Insulin receptor autophosphorylation
and IRS-1 tyrosine phosphorylationwere also reduced in vivo
in the livers of mice after chronic infusion with IL-6 (12). On
the other hand, in the same study, no effect was found on
skeletal muscle. In addition, IL-6 administration to myocytes
in culture hadno effect on insulin action (13) and a short-term
infusion of IL-6 in rats did not affect insulin sensitivity or
whole-body glucose uptake (14). A studywith healthy young
men showed that the infusion of high amounts of recombi-
nant human IL-6 did not alter glucose uptake or oxidation.
This shows that acute high concentrations of IL-6 might not
disturb insulin sensitivity or glucose disposal in skeletal
muscle in healthy subjects (15).
The observation that increased IL-6 concentrations are as-
sociated with DM2 leads to the suggestion that the systemic
production of IL-6 is increased in the insulin-resistant state.
It is known that adiposity plays a role in subclinical inflam-
mation, because adipose tissue produces inflammation
markers like IL-6 (16). Recently however, the skeletal muscle
has become an interesting organ in the production of IL-6 as
well, because it released IL-6 during and after exercise (17,
18). So far, few studies addressed the role of muscle IL-6
production in man in the development of insulin resistance
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in conditions like IGT and DM2. During exercise, no signif-
icant differences were found in muscle IL-6 production in
skeletal muscle between controls and DM2 patients (19).
However, an important stressor next to exercise is the intake
of a high-fat meal. In particular in DM2, the impaired han-
dling of substrates in the postprandial phase may be of im-
portance in the development or deterioration of insulin re-
sistance and hyperglycemia. It has been found before that
venous IL-6 concentrations increased after a high-fat meal in
obese men (20). Additionally, it has been shown that after a
high-fat meal, the venous IL-6 concentrations slightly in-
creased in healthy overweight subjects, and increased even
more in newly diagnosed diabetic subjects (21).
The aim of this study was to examine 1) whether skeletal
muscle produces IL-6 during fasting or in the postprandial
phase; 2) whether the production of IL-6 by skeletal muscle
is increased in obese men with IGT compared with obese
men with NGT; and if so, 3) whether the production of IL-6
in skeletal muscle changes after weight loss in IGT men. In
parallel with IL-6, other inflammatory markers like CRP and
TNF- receptors were monitored.
Subjects and Methods
Subjects
Eleven obese men with IGT and nine obese men with normal glucose
tolerance (NGT) matched for age and body mass index (BMI) partici-
pated in the study. Inclusion criteria were obesity (BMI  30 kg/m2),
diastolic blood pressure less than 100mmHg, nomajor health problems,
and no use of medication that could influence the measurements. The
IGT men had no family history of diabetes. Subjects were not involved
in any regular physical activity for more than 3 h a week. The partic-
ipants were asked not to change their physical activity and smoking
habits during the study. One IGT person smoked. The experimental
protocol was approved by the local Medical Ethical Committee of the
Maastricht University. All subjects gave written informed consent.
Glucose tolerance, body composition, aerobic capacity, and
insulin sensitivity
Subjects were screened for glucose metabolism with a standard oral
glucose tolerance test (75 g glucose) with capillary blood sampling at
baseline and after 2 h. Subjects were included according to the World
Health Organization criteria of 1999 for capillary plasma (IGT: fasting
7.0mmol/liter, 2 h postload8.9 and12.2mmol/liter). Two subjects
with glucose values (fasting 8.0 mmol/liter and 2 h postload 14.8
mmol/liter) above the cutoff points were included as well. After inclu-
sion, fat mass and fat-free mass (FFM) were determined by underwater
weighing with correction for residual lung volume (Volugraph 2000;
Mijnhardt, Bunnik, The Netherlands) and calculated according to Siri
(22). Extracellular water was estimated using bio-impedance (Hydra;
Xitron Utilities, San Diego, CA). Maximal aerobic power (Wmax) and
peak oxygen uptake (VO2peak) were determined during an incremental
exhaustive exercise test on an electronically braked bicycle ergometer
(Lode, Groningen, The Netherlands). Insulin sensitivity was measured
with a hyperinsulinemic euglycemic clamp (23). Insulin (1 mUkg
BW1min1) was infused at a constant rate with glucose clamped at 4.6
mmol/liter with an iv infusion of 20%wt/vol glucose infusion. M value
was calculated as the glucose infusion rate (millimoles of glucose per
minute) per kilogram FFM during a steady-state of 30 min after at least
120 min of insulin infusion.
High-fat meal test
Subjects were informed to refrain from heavy exercise like organized
sports activities or heavy physical work and to consume a carbohydrate-
rich dinner like pasta the day before the test. Subjects came to the
laboratory by car or public transport after an overnight fast (12–14 h),
during which they were only allowed to drink water. Forearm skeletal
muscle was studied with the forearm model by measuring arterio-
venous concentration differences across the muscle in combination with
forearm blood flow measurements (24). Two catheters were inserted,
one in the arteria radialis and one in a retrograde direction into a deep
forearm vein. The O2-saturation in the deep venous forearm samples
was less than 60%, implying that deep venous blood was drawn mainly
from skeletal muscle. Blood sampling and blood flow measurements
took place before and after a high-fat meal. The meal provided 2.6 MJ,
which consisted of 61 energy percent (E%) from fat (of which 35.5 E%
saturated, 18.8 E% monounsaturated, and 1.7 E% polyunsaturated fat),
33 E% carbohydrates and 6 E% protein. To exclude metabolism in the
hand, the hand circulation on the side of the deep venous catheter was
occluded (200 mm Hg) at every measurement. Immediately after oc-
clusion, blood flow was measured with venous occlusion plethysmog-
raphy (EC5R plethysmograph; Hokanson, Bellevue, WA). One minute
after occlusion, arterial and deep venous blood samples were simulta-
neously drawn in EDTA syringes (1.5 mg EDTA/ml) for plasma anal-
yses before (at60,30, and 0min) and 30, 60, 90, 120, 180, and 240min
after the test meal. Blood samples were immediately centrifuged and
plasma was frozen in liquid nitrogen and stored for analysis at 80 C.
Plasma flow was calculated as bloodflow[1  (hematocrit/100)]. Me-
tabolite fluxes were calculated as arterio-venous differences of metab-
olites multiplied by plasma flow. A positive flux is uptake from plasma
and a negative flux is release by muscle.
Weight loss period
After the measurements, eight men from the IGT group were willing
to followa 12-wkweight loss programandvisited adietitian everyweek.
Everyweek the subjectswereweighed and capillary plasma glucosewas
checked. During the first 4 wk, the subjects were provided with a very
low calorie diet (2 MJ/d) based on shakes (Modifast; Nutrition et Sante´,
Breda, The Netherlands) containing all the essential macro- and micro-
nutrients. Beside the shakes, subjects were stimulated to eat at least 150 g
of raw nonstarchy vegetables each day. From wk 5–8, the shakes were
gradually replaced by meals, increasing the energy content of the diet
up to 4.2 MJ/d. In wk 8–12, the subjects were kept in energy balance by
prescribing detailed weekly menus. All measurements, i.e. clamp, fore-
arm model, hydrostatic weighing, and the exercise test, were repeated
in wk 11 and 12.
Biochemical analysis
Plasma free fatty acids and glucose were analyzed using standard
enzymatic techniques automated on the COBAS Fara centrifugal ana-
lyzer at 340 nm (for FFA: FFA-C test kit, Wako Chemicals, Neuss,
Germany; for glucose: Roche Unikit III, Hoffman-la-Roche, Basel, Swit-
zerland). Insulin was analyzed using a fluoroimmunometric assay (au-
toDELFIA Insulin; PerkinElmer, Turku, Finland) with no cross-reactiv-
ity with proinsulin or split forms of proinsulin. IL-6 was analyzed with
an ultra-sensitive ELISA kit (Quantikine HS SixPak; R&D Systems,
Abingdon, UK; intraassay coefficient of variation (CV) of 3.8%), Soluble
CRP (CRP-s) was analyzed on an autoanalyzer Hitachi 912 (High Sen-
sitive kit 11972855; Roche, Almere, The Netherlands; intraassay CV of
2.6%). The TNF receptors R1 and R2 (soluble) were analyzed with an
ELISA kit from Biosource (TNF-R1/p55: KAC1762, intraassay CV of
7.9%; TNF-R2/p75: KAC1772, intraassayCVof 6.6%;Nivelles, Belgium).
All metabolites were analyzed in duplicate (duplicate CV  10%).
Statistical analysis
NGT and IGT men were compared with a two-tailed Student’s t test
for independent samples. IGT men before and after weight loss were
compared with a two-tailed Student’s t test for paired samples. For
fasting values the average of time points60,30, and 0minwas taken.
For postprandial responses the total areas under the curve (AUC) di-
vided by time (AUC/min) were compared. Results in the tables and text
are given in mean  sd. Data in the figures are given in mean  sem.
A P value less than 0.05 was considered as statistically significant.
Statistical analysis was performed using SPSS 10.0 for Macintosh.
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Results
General
No differences were seen in age, BMI, body fat percentage,
and aerobic capacity between the IGTmen and theNGTmen.
Insulin sensitivity was not significantly different (Table 1).
Fasting metabolites and postprandial response in
forearm muscle
Fasting concentrations of glucose, insulin, and free fatty
acids were not different between IGT and NGT men. Post-
prandially, arterial glucose tended to increase more (P 
0.10) in the IGTmen, but the postprandial increase of arterial
insulin and the postprandial decrease of arterial free fatty
acid concentrationswere not different betweenNGTand IGT
(Table 2). Arterial IL-6 concentrations were not different be-
tween groups in the fasting state, nor after the meal. How-
ever, deep venous IL-6 concentrationswere higher in the IGT
men during fasting (IGT 3.89 1.99 vs.NGT 2.31 0.73
pg/ml, P  0.03) and in the postprandial phase (AUC/min:
IGT  5.06  3.18 vs. NGT  2.86  0.77 pg/ml, P  0.05;
Fig. 1). Similar differences were found for IL-6 flux, because
blood flow was not different between groups during fasting
(NGT  1.51  0.47; IGT  1.78  0.60 ml100 ml
tissue1min1) or after a meal (AUC/min, NGT  1.82 
0.62; IGT  1.97  0.85 ml100 ml tissue1min1). It was
found that the IL-6 release frommusclewas higher in the IGT
group than in theNGT group, both in the fasting state (IGT
2.26  1.89 vs. NGT  0.87  0.48 fmol100 ml
tissue1min1, P  0.04) and in the postprandial phase
(AUC/min: IGT  3.48  2.63 vs. NGT  1.37  0.75
fmol100 ml tissue1min1, P 0.03; Fig. 2). The postpran-
dial IL-6 release (AUC/min) was higher than the fasting IL-6
release (P  0.05) in the group as a whole. Arterial CRP,
TNF-R1, and TNF-R2 concentrations were not different be-
tween groups (Table 3). CRP, TNF-R1, and TNF-R2 arterio-
venous differences were all less than 1% of arterial concen-
trations. Subsequently all fluxes were around zero, showing
that CRP, TNF-R1, and TNF-R2 were not released frommus-
cle, neither in the fasting nor in the postprandial phase.
Extrapolated estimated muscle IL-6 production
It can be calculated to what extent the release of IL-6 from
muscle can contribute to systemic IL-6 levels. It has to be
taken into account that these are calculated estimates, partly
based on assumptions. We assumed that muscle mass, esti-
mated as approximately 55% (25) of FFM, released IL-6 at the
same rate as the forearm muscle studied here, and used
an estimated half-life of 3 min (26). We estimated the
IL-6 production rate of total muscle mass during fasting
(meanTOTAL GROUP  0.58 ng/min, range 0.12–2.11 ng/min)
and postprandially (meanTOTAL GROUP 0.90 ng/min, range
0.06–2.61 ng/min). The estimated contribution of IL-6 re-
lease from skeletalmuscle to systemic IL-6, usingwhole body
extracellular fluid estimated from bio-impedance (Hydra;
Xitron Utilities), was 12% (range 2–42%) for the whole group
in the fasting state. In the postprandial phase it was 11%
(range 2–21%) in NGT men and highest in IGT men (25%,
range 2–66%).
Effect of weight loss
Eight IGT men were willing to participate in the weight
loss program. They lost on average 15.0  3.4 kg of body
weight (Table 1). Approximately 72% of this weight loss was
owing to a reduced fat mass and 28% to a reduction in FFM.
Body weight was 82.4  8.3 kg in wk 8, at the end of the
weight loss period, and 82.5  9.4 kg in wk 10, just before
repeating the measurements, indicating that subjects were in
energy balance during the measurement period. Weight loss
improved insulin sensitivity (Table 1), reduced fasting arte-
rial glucose, insulin, and free fatty acid concentrations and
reduced postprandial hyperglycemia (8%) and hyperinsu-
linemia (41%) (Table 2). No change was seen in aerobic
capacity (Table 1).
After weight loss (WL), no significant change was ob-
served in fasting arterial IL-6 concentrations (Table 3) or
fasting IL-6 release from muscle (IGTPRE WL: 2.22  1.86 vs.
IGTAFTER WL: 1.40 1.32 fmol100 ml tissue
1min1; Fig. 1;
P  0.24), but postprandial IL-6 release had decreased
(IGTPRE WL: 2.99 2.58 vs. IGTAFTER WL: 1.45 1.33 fmol100
ml tissue1min1,P 0.04) afterweight loss (Fig. 2).Weight
TABLE 1. General and metabolic characteristics of the obese men
NGT (n  9) IGT (n  11)
IGT
Before WL (n  8) After WL (n  8)
Age (yr) 55.9  7.2 55.5  7.9 56.1  8.4
Body weight (kg) 107.0  19.2 95.9  7.8 95.2  7.6 80.2  7.6a
FFM (kg) 69.5  10.8 64.8  5.0 63.2  3.6 58.9  4.2a
BMI (kg/m2) 34.6  4.8 32.1  2.3 32.2  4.4 27.5  1.5a
Body fat % 34.6  6.0 32.5  3.0 33.6  2.1 26.3  3.6a
Waist to hip ratio 1.02  0.05 1.03  0.04 1.04  0.03 0.99  0.03a
VO2peak (ml O2kg FFM
1min1) 39.7  6.0 41.0  4.8 39.7  4.3 40.9  7.2
Glucose, fasting (capillary, mmol/liter) 5.7  0.6 6.5  0.9b 6.7  1.0 n.d.
Glucose, 2 h after 75-g glucose load
(capillary, mmol/liter) (mg/dl)
6.7  1.2 11.9  2.0c 12.7  2.0 n.d.
Insulin sensitivity
(M value, molkg FFM1min1)
32.4  14.3 24.5  10.8 23.3  9.4 39.2  11.7a
n.d., Not determined.
a P  0.01 IGT before weight loss vs. after weight loss; paired test with n  8.
b P  0.05 NGT vs. IGT.
c P  0.01 NGT vs. IGT.
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loss also decreased the arterial CRP level (45%, P  0.004,
Table 3), whereas the TNF-R1 receptor showed a trend for a
lower concentration (7%,P 0.06, Table 3). No correlations
between M value, body weight loss, and IL-6 release were
found.
Discussion
A major finding of the present study is that the cytokine
IL-6 was released from skeletal muscle of obese IGT and
obese NGT men during fasting and after a high-fat meal.
Interestingly, the IL-6 release from forearm muscle was
higher in obese men with IGT compared with obese men
with NGT. Furthermore, in IGT men, the IL-6 release from
muscle after a high-fat meal was reduced after weight loss,
in concert with improvements in insulin sensitivity and glu-
cose tolerance.
It has been reported before that the venous IL-6 concen-
tration increases after a meal, especially after a high-fat meal
(20, 21). This is the first report describing IL-6 release in the
postprandial phase by skeletal muscle. In the present study,
it can be calculated that the estimated total muscle mass
would produce 7 vs. 16% of the systemic IL-6 during fasting
and 11 vs. 25% in the postprandial phase for NGT and IGT
subjects, respectively. Mohamed-Ali et al. (27) previously
reported that the estimated production rate of whole body
adipose tissue was 1.41 ng/min (range 0.22–2.67 ng/min),
which was in the same range as the values we found for
muscle in the postprandial phase in IGT men before weight
loss (1.17 ng/min, range 0.15–2.61 ng/min). Thus, both ad-
ipose tissue and skeletal muscle contribute to circulating IL-6
concentrations. The question remains whether the IL-6 is
produced by myocytes or by other cell types present in mus-
cle, because it has recently been found that the IL-6 release
from adipose tissue derives 90% from nonadipocytes (28).
Although it is known that IL-6 can be released by muscle
fibers themselves (13, 29), the contribution of other cell types
such as monocytes/macrophages, endothelial cells, fibro-
blasts, and smooth muscle cells cannot be excluded. The
contribution of other tissues in the forearm, like adipose
tissue, cannot be entirely excluded either, although the deep
venous plasmawasmainly drawn frommuscle, as confirmed
by an O2-saturation less than 60%.
It is still unclear what may trigger IL-6 release from mus-
cle.We cannot even exclude that the experimental conditions
per se may have had an effect on IL-6 release from muscle,
because we did not include a control group for the meal-
effect. Nevertheless, it is likely that the meal per se evoked an
FIG. 1. Arterial and deep venous concentrations of IL-6 across fore-
arm muscle during fasting and after a meal; compare NGT and IGT
men. Arterial IGT (E), deep venous IGT (F), arterial NGT (), deep
venous NGT (f). Means  SEM. Groups were compared with an un-
paired Student’s t test: arterial IL-6 concentration during fasting,P
0.492; deep venous IL-6 concentration, P  0.031; postprandial AUC
for arterial IL-6 concentration, P 0.698; postprandial AUC for deep
venous IL-6 concentration, P  0.049. Arterial vs. venous concentra-
tions, paired Student’s t test: all differences P  0.01.
FIG. 2. IL-6 flux over skeletalmuscle during fasting and after ameal;
compare obeseNGTmen (obeseNGT, n 9) with obesemenwith IGT
before (obese IGT, n 11) and after weight loss (IGT after weight loss,
n  8). NGT men (f), IGT men before weight loss (F), IGT men after
weight loss (‚). Means  SEM. NGT men and IGT men before weight
loss were compared with a Student’s t test for independent samples:
IL-6 flux during fasting, P  0.038; postprandial AUC for IL-6 flux,
P 0.026. IGTmen (n 8) before andafterweight losswere compared
with a Student’s t test for paired samples: IL-6 flux during fasting,P
0.301; postprandial AUC for IL-6 flux, P  0.042.
TABLE 2. Fasting and postprandial arterial concentrations of glucose, insulin, and free fatty acids in men with NGT, IGT, and IGT after
weight loss
NGT (n  9) IGT (n  11)
IGT
Before WL (n  8) After WL (n  8)
Glucose, fasting (mmol/liter) 5.8  0.3 6.0  0.5 5.9  0.6 5.3  0.5a
Postprandial AUC 6.57  0.47 7.08  0.65b 7.07  0.75 6.47  0.33a
Insulin, fasting (mU/liter) 18.0  12.7 14.4  3.8 14.3  4.5 6.5  3.1c
Postprandial AUC 31.5  13.7 38.2  14.7 34.5  11.5 20.9  9.0a
Free fatty acid, fasting (mol/liter) 555  166 675  184 697  201 556  102a
Postprandial AUC 359  70 440  148 473  163 360  92a
Mean  SD. Postprandial AUC as mean per minute (AUC/min).
a P  0.05 IGT before weight loss vs. after weight loss; paired test with n  8.
b P  0.10 difference between NGT and IGT.
c P  0.01 IGT before weight loss vs. after weight loss; paired test with n  8.
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effect on IL-6 release, because the postprandial IL-6 release
(AUC/min) was higher than the fasting IL-6 release (P 
0.05) in the group as a whole. Several factors may provoke
IL-6 release frommuscle. In the first place, the production of
cytokines in skeletal muscle, like IL-6, may be stimulated by
oxidative stress (30). One of the factors that may cause ox-
idative stress in the postprandial period is impaired substrate
handling (31), as described in IGT and DM2 (24, 32). Im-
pairments in lipid (33) and glucose (34) handling may both
lead to oxidative stress. In the second place, impairments in
lipidmetabolism, like a reduced oxidation of plasma-derived
fatty acids (24, 32) in DM2 subjects may lead to the accu-
mulation of interstitial or cytosolic free fatty acids. Especially
saturated fatty acids like palmitate can directly stimulate the
production of IL-6 inmyocytes fromDM2patients (13),when
present in abundance. So, impairments in substrate han-
dling, as found in IGT and DM2, may lead to the production
of free radicals, and/or to an increment of local concentra-
tions of saturated free fatty acids. Each of thesemay stimulate
the production of IL-6 in the postprandial phase. The phys-
iological significance of IL-6 release from muscle is still un-
clear. Pedersen et al. (35) suggested that IL-6 may be an
interorgan signaling molecule during exercise, reporting a
signal from skeletal muscle to the liver to indicate the use of
glycogen. However, this is not likely to be the case after meal
intake.
What may be the effect of the cytokines that are produced
on skeletal muscle metabolism? It has been shown that sys-
temic IL-6 infusion, resulting in high arterial IL-6 concen-
trations (150 pg/ml), stimulates lipolysis and fatty acid
oxidation in humans in rest (36), although it is not known
whether similar effects will be found in the physiological
range. However, in adipose tissue, it has been shown that
interstitial IL-6 concentrations may be up to approximately
100 times as high as plasma values (37). Likewise, high in-
terstitial amounts of IL-6 may affect fatty acid metabolism in
an auto- or paracrine manner. On the other hand, it has been
reported that IL-6 infusion did not affect glucose uptake or
oxidation, and in vitro and in vivo studies show no effect of
IL-6 on insulin action in skeletal muscle (12–14). However,
IL-6 may induce tissue insulin resistance in other organs, e.g.
in liver (11, 12), thus contributing to the further progression
of IGT to DM2.
After weight loss, arterial IL-6 concentrations had not
changed, but the postprandial release of IL-6 from muscle
was decreased (52%, P  0.04). This improvement in IL-6
release after weight loss may have been a consequence of the
reduction in body weight, the improvement of glucose tol-
erance and/or the increase in insulin sensitivity. This sup-
ports the concept that the postprandial increase in IL-6 pro-
duction may have been triggered by disturbances in glucose
and/or fat metabolism found in obese IGT men.
The lack of differences between NGT and IGT subjects in
arterial concentrations of IL-6, CRP, TNF-R1, and TNF-R2 is
in accordance with some (5, 38), but not all studies (3) and
may be explained by the fact that the observed groups are
equally obese and only slightly different in insulin resistance.
In conclusion,we observed IL-6 release from forearmmus-
cle in obese NGT and obese IGT subjects, both during fasting
and after a meal. IL-6 release was significantly higher in IGT
men during the postprandial phase when compared with
obese NGT men. In these IGT men, the postprandial IL-6
release decreased after body weight loss, reaching levels that
were found in the obese, NGT controls. We suggest that the
high-fat meal may be an important metabolic stressor, evok-
ing IL-6 release from skeletal muscle, due to the impairment
in substrate handling in IGT men and that the IL-6 produc-
tion may rather be a consequence than a cause of the obese,
insulin-resistant and/or IGT state. Further studies have to
provide more information on the mechanisms that are re-
sponsible for the increased IL-6 production by muscle, and
whether the production of IL-6 in muscle may lead to a
further increase in insulin resistance, contributing to the pro-
gression of IGT to DM2.
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